Shanghai Fosun Pharmaceutical (600196.SH): The drug registration application for Sodium Hyaluronate Injection has been approved.
Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary Chongqing Kailin Pharmaceutical Co., Ltd. has obtained the approval from the National Medical Products Administration for the drug registration application of Sodium Thiosulfate Injection. This approval is for the treatment of cyanide poisoning, as well as arsenic, mercury, lead, bismuth, iodine, and other poisonings.
Shanghai Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary Chongqing Kailin Pharmaceutical Co., Ltd. has obtained approval from the National Medical Products Administration for the drug registration application of Sodium Thiosulfate Injection. The approved indications for this drug include use in cyanide poisoning, as well as in poisoning from arsenic, mercury, lead, bismuth, iodine, and others.
Related Articles
Annual Report Revelation of CHINA HONGQIAO (01378): Firm Growth as the Foundation, Strengthening Dividend Attributes Further
GMTEight List of A-share restricted sales and lifting restrictions | March 23rd
Siasun Robot&Automation (01021) Launches IPO: How well can the Chinese collaboration Siasun Robot&Automation perform as a "overseas sales champion"?
Annual Report Revelation of CHINA HONGQIAO (01378): Firm Growth as the Foundation, Strengthening Dividend Attributes Further
GMTEight List of A-share restricted sales and lifting restrictions | March 23rd
Siasun Robot&Automation (01021) Launches IPO: How well can the Chinese collaboration Siasun Robot&Automation perform as a "overseas sales champion"?
RECOMMEND
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026
